Company* |
Product | Description | Indication |
Status |
AUTOIMMUNE | ||||
Arakis Ltd.* |
AD 452 |
Small-molecule disease- modifying anti-rheumatic drug | Rheumatoid arthritis |
Phase II trial with methotrexate in 99 patients showed the drug was safe and well tolerated (4/7) |
Biogen Idec |
Tysabri |
Natalizumab; humanized monoclonal antibody that inhibits adhesion molecules on immune cells | Multiple sclerosis |
Two-year data from AFFIRM Phase III monotherapy trial in 942 patients met all primary and secondary endpoints, including disability progression and relapse rate (4/12) |
Chiron Corp. |
Betaseron |
Interferon beta-1b |
Multiple sclerosis | Preliminary data from 16-year trial show safety and benefit of the drug over the long term (4/14) |
Genentech |
Rituxan |
Rituximab; antibody that binds to the CD20 antigen on the surface of normal and malignant B cells | Rheumatoid arthritis |
Phase III REFLEX trial showed drug with methotrexate displayed a statistically significant improvement in symptoms vs. placebo and methotrexate in those who inadequately responded to anti- TNF therapies (4/6) |
Human Genome |
LymphoStat-B |
Belimumab; human monoclonal antibody that inhibits activity of B-lymphocyte stimulator | Rheumatoid arthritis |
Phase II trial in 283 patients showed safety and tolerability, and a reduction in RA signs and symptoms in a statistically significant manner (4/6) |
Serono SA |
Onercept |
Recombinant tumor necrosis factor binding protein | Psoriasis |
Phase III trials were stopped after 12 weeks due to an inadequate risk-benefit profile; two patients developed sepsis (4/6) |
CANCER | ||||
Adventrx |
CoFactor |
Form of folic acid designed to enhance the antitumor effects of 5-FU | Metastatic colorectal cancer |
Is starting a pivotal Phase III trial under an FDA SPA that will test drug vs. leucovorin in a chemotherapy regimen in 600 patients (4/25) |
Adventrx |
CoFactor |
Form of folic acid designed to enhance the antitumor effects of 5-FU | Metastatic colorectal cancer |
Data from ongoing Phase II trial suggest there is negligible risk of toxicity from the drug (4/19) |
Agennix Inc.* |
Talactoferrin | Oral, recombinant human lactoferrin |
Advanced non- small-cell lung cancer |
Phase II trial in 110 patients showed improved responses with drug plus chemotherapy regimen vs. the regimen plus placebo (4/19) |
Alfacell Corp. |
Onconase |
Ranpirnase; cytotoxic ribonuclease | Non-small-cell lung cancer |
Trial data showed drug enhanced chemosensitivity with cisplatin or carboplatin, with manageable toxicity (4/20) |
American |
Abraxane (FDA-approved) |
Paclitaxel protein-bound particles for injection; albumin-bound | Metastatic breast cancer |
Began Phase II trial to test the drug with Herceptin in first-line treatment in 70 patients with with locally advanced or metastatic disease (4/4) |
Amgen Inc. |
Panitumumab |
Fully human monoclonal antibody that targets the epidermal growth factor receptor | Metastatic colorectal cancer |
Began Phase III PACCE trial to evaluate the drug with other agents in first-line treatment in about 1,000 patients (4/26) |
Antisoma plc |
AS1404 |
Vascular-targeting agent designed to disrupt tumor blood vessels | Hormone- refractory prostate cancer |
Is starting a Phase II trial of the drug in combination with docetaxel (4/19) |
A.P. Pharma |
APF530 |
The anti-emetic granisetron in a polymer-based drug delivery system | Chemotherapy- induced nausea and vomiting |
Began Phase II trial to test safety, tolerability and pharmacokinetics in up to 30 patients (4/28) |
CancerVax |
Canvaxin |
Therapeutic whole-cell vaccine that expresses more than 20 antigens | Stage IV melanoma |
Monitors recommended stopping the Phase III trial after a second interim analysis showed the data are unlikely to provide a survival benefit vs. placebo; a Phase III trial in Stage III melanoma continues (4/6) |
Celgene |
Revlimid |
Lenalidomide; derivative of Thalomid (thalidomide) | Multiple myeloma |
Phase III trial in 354 relapsed or refractory patients showed a statistical significance with dexamethasone vs. dexamethasone alone in time to disease progression (4/11) |
Cell Genesys |
CG0070 |
Oncolytic virus therapy engineered to include the therapeutic gene for GM-CSF | Recurrent bladder cancer |
Began Phase I trial to evaluate safety, dosing and responses in 36 patients who have failed BCG therapy (4/26) |
Cell |
Trisenox (FDA-approved) | Arsenic trioxide |
Multiple myeloma | Phase II trial with MAC regimen showed objective responses in 22 of the 37 relapsed or refractory patients (4/11) |
ChemGenex |
Ceflatonin |
Homoharringtonine | Chronic myelogenous leukemia |
Began Phase II trial in combination with Gleevec in CML patients who have developed resistance to Gleevec (4/7) |
Chiron Corp. |
CHIR-12.12 |
Fully human, antagonist antibody that targets the CD40 antigen | Advanced chronic lymphocytic leukemia |
Began single-agent trial in 40 patients to evaluate safety, dosing, tolerability and pharmaco-kinetics (4/18) |
Genentech |
Herceptin |
Trastuzumab; monoclonal antibody against HER2/neu protein | HER2-positive breast cancer |
Two Phase III trials in nearly 5,500 early stage patients were stopped early after an interim analysis showed improvements in disease-free and overall survival (4/25) |
Genentech |
Avastin (FDA-approved) | Bevacizumab; antibody designed to inhibit vascular endothelial growth factor | Metastatic breast cancer |
Interim data from Phase III trial in 722 patients showed drug plus paclitaxel in first-line treatment improved progression-free survival vs. chemotherapy alone (4/15) |
Genmab A/S |
HuMax-CD4 |
Zanolimumab; human antibody that targets the CD4 receptor on T lymphocytes | Cutaneous T-cell lymphoma |
Reached agreement with FDA on SPA for pivotal trial that first will test new antibody material in 18 patients, then will test response rates in 70 patients (4/19) |
GlycoGenesys |
GCS-100LE |
Ethanol-free formulation of the company's GCS-100 complex carbohydrate drug | Multiple myeloma |
Began Phase I/II trial to evaluate safety, dosing and responses as a monotherapy and in combination therapy (4/5) |
GPC Biotech |
Satraplatin |
Oral platinum compound | Hormone- refractory prostate cancer |
Monitors in the Phase III SPARC trial recommended the trial continue after reviewing safety data from the first 262 patients (4/19) |
Human Genome |
HGS-ETR1 |
Agonistic human monclonal antibody to TRAIL receptor 1 |
Advanced solid tumors | Phase I trial in 44 patients showed safety and tolerability; stable disease was observed in 10 patients (4/18) |
Incyte Corp. |
INCB7839 |
Inhibitor of sheddase, an enzymatic activity attributed to the ADAM family of proteins | Solid tumors |
Began a Phase I trial to assess the safety and pharmacokinetics in healthy volunteers (4/6) |
Kosan |
KOS-862 |
Epothilone D, a polyketide | Metastatic breast cancer |
Monitors recommended Phase II monotherapy trial continue to full enrollment following an interim analysis (4/5) |
Lorus |
GTI-2040 |
Antisense oligonucleotide complementary to the R2 component of ribonucleotide reductase | Advanced renal-cell carcinoma |
Final data from Phase II trial in 33 patients confirmed promising interim findings reported earlier (4/12) |
Medarex Inc. |
MDX-010 and MDX-1379 |
Fully human anti-CTLA-4 antibody; gp100 melanoma peptide vaccine | Metastatic melanoma |
Seven of 56 patients in Phase II trial achieved complete or partial responses, with five responses ongoing for more than two years (4/20) |
Millennium |
Velcade (FDA-approved) | Bortezomib; proteasome inhibitor |
Lung cancer | Began Phase II PEAK trial in patients with either advanced bronchioalveolar carcinoma (BAC) or adenocarcinoma with BAC features that has progressed (4/25) |
Millennium |
Velcade (FDA- approved) | Bortezomib; proteasome inhibitor |
Multiple myeloma | Presented data from single-agent and combination studies showing benefit across the MM treatment paradigm (4/13) |
Myriad |
MPC-6827 |
Pro-apoptotic drug candidate | Solid tumors |
Began Phase I trial to evaluate safety and pharmacokinetics in patients with advanced tumors (4/27) |
NeoPharm |
IL13-E38QQR |
Tumor-targeting agent designed to deliver bacterial cytotoxic PE38 | Glioblastoma multiforme |
Updated data from Phase I trial in 42 patients showed prolonged progression-free survival (4/18) |
Novacea Inc.* |
AQ4N | Banoxantrone; hypoxic cell- activated antitumor therapy | B-cell neoplasms |
Began Phase I/II trial in up to 55 patients to evaluate safety, tolerability, pharmacokinetics, dosing and responses (4/20) |
Oncolytics |
Reolysin |
Formulation of the human reovirus | Advanced solid tumors |
Began Phase I trial to evaluate dosing, safety and activity in up to 36 refractory patients (4/7) |
Onyx |
BAY 43-9006 (sorafenib) | RAF kinase and VEGF inhibitor |
Advanced renal- cell carcinoma |
Interim data from Phase III trial showed significant improvement in the duration of disease stabilization; decision was made to offer the drug to all patients in the trial (4/18) |
PharmaMar |
Yondelis |
Trabectedin; ET-743; derived from the sea squirt Ecteinascidia turbinata | Ovarian cancer |
Began a Phase III trial to compare drug plus liposomal doxorubicin to the liposomal drug alone in 650 patients (4/4) |
Point |
Talabostat (PT-100) |
Small molecule designed to stimulate proliferation of hematopoietic progenitor cells | Non-small-cell lung cancer |
Phase II trial with docetaxel achieved the desired tumor response criteria; the patients had Stage IIIb/IV NSCLC (4/28) |
Vion |
Cloretazine (VNP40101M) | Sulfonylhydrazine DNA alkylating agent |
Pediatric brain tumors | The Pediatric Brain Tumor Consortium began a Phase I trial in children to evaluate dosing (4/13) |
ZioPharm Inc.* |
ZIO-101 | Organic arsenic compound |
Hematological cancers | Starting a Phase I dose-ranging trial in patients (4/5) |
CARDIOVASCULAR | ||||
Affymax Inc.* |
Hematide | Peptide-based erythropoiesis-stimulating agent | Anemia |
Began a Phase II trial to evaluate safety and pharmacokinetics in patients with chronic kidney disase who are not on dialysis (4/7) |
American |
Coroxane |
Nanoparticle, albumin- bound paclitaxel | In-stent restenosis |
Phase I study in 23 patients produced information on dosing (4/5) |
Cardiome |
RSD1235 |
Oral formulation of drug designed to selectively block ion channels in the heart | Atrial fibrillation |
Phase Ib trial showed drug was absorbed and tolerated; company began a Phase Ic trial to assess multi-day dosing (4/25) |
Cardiome |
Oxypurinol |
Xanthine oxidase inhibitor that is the active metabolite of allopurinol | Congestive heart failure |
Physician-sponsored EXOTIC-EF trial in 20 patients showed a statistically significant improvement in left ventricle ejection fraction (4/7) |
CV |
Ranexa (ranolazine) |
Partial inhibitor of fatty- acid oxidation | Chronic angina |
Phase III ERICA trial run under FDA SPA in 565 patients met the primary endpoint of reducing weekly angina frequency vs. placebo (4/18) |
GTC |
ATryn |
Recombinant human antithrombin | Hereditary antithrombin deficiency |
Starting a safety and efficacy trial in at least 17 HD patients who are undergoing high-risk procedures; the data will be combined with an earlier 14-patient trial used in an EMEA MAA filing (4/6) |
ImaRx |
SonoLysis |
Therapy that uses ultrasound to cavitate gas- filled microbubbles to dissolve blood clots | Acute ischemic stroke |
Began Phase II trial in 40 patients to test if ultrasound can safely enhance the clot-dissolving ability of t-PA (4/5) |
ImaRx |
SonoLysis |
Therapy that uses ultrasound to cavitate gas-filled microbubbles to dissolve blood clots | Peripheral arterial occlusive disease |
Began a Phase I/II trial to evaluate safety and efficacy in 12 patients (4/12) |
ImaRx |
SonoLysis |
Therapy that uses ultrasound to cavitate gas-filled microbubbles to dissolve blood clots | For use in clotted dialysis grafts |
Phase I/II trial in 22 dialysis patients showed no safety concerns, and improvements in the study's endpoints (4/1) |
Medicure Inc. |
MC-1 |
Small-molecule cardioprotective agent | For use in coronary artery bypass graft surgery | Monitors recommended continuation of the Phase II/III MEND-CABG trial following a safety review (4/19) |
Northfield |
PolyHeme |
Oxygen-carrying blood substitute derived from human blood | Blood loss |
Monitors recommended Phase III trial in treating hemorrhagic shock following traumatic injury continue, after third interim analysis involving 250 patients (4/11) |
Nuvelo Inc. |
Alfimeprase |
Modified fibrolase delivered via catheter; thrombolytic agent | Acute peripheral arterial occlusion |
Began Phase III NAPA-2 trial in 300 patients to measure avoidance of open vascular surgery within 30 days of treatment (4/18) |
CENTRAL NERVOUS SYSTEM | ||||
Alkermes Inc. |
Vivitrex |
Long-acting, injectable form of naltrexone | Alcohol dependence |
Phase III trial in 624 patients showed a statistically significant reduction in the rate of heavy drinking relative to placebo (4/5) |
Avanir |
Neurodex |
Oral combination of dextromethorphan and an enzyme inhibitor, quinidine | Pseudobulbar affect |
Phase III trial in 150 multiple sclerosis patients with PBA showed improvements in several endpoints (4/14) |
Ceregene |
CERE-110 |
Gene therapy that uses AAV2-based vector to deliver nerve growth factor | Alzheimer's disease |
Phase I trial in six patients showed the agent was tolerable, and reduced cognitive decline (4/25) |
Guilford |
Aquavan |
Water-soluble prodrug of propofol | Sedation |
Reached agreement with FDA on a revised clinical development plan; it intends to re-initiate previously planned studies (4/21) |
Memory |
MEM 1414 and MEM 1917 |
Phosphodiesterase-4 inhibitors | Alzheimer's disease and depression |
Partner Hoffmann-La Roche Inc. decided not to pursue further development of the compounds, neither of which had gone past Phase I trials (4/15) |
Neurochem |
Alzhemed |
Small molecule designed to interfere with association between glycosamino- glycans and A-beta protein | Alzheimer's disease |
Monitors recommended continuation of Phase III trial after reviewing safety data from 562 patients (4/27) |
Neurologix |
-- |
GAD gene delivered by adeno-associated virus viral vector | Parkinson's disease |
Update on Phase I trial showed no treatment-related adverse effects; 11 patients have been followed up to a year or more (4/22) |
NovaDel |
-- |
Lingual spray version of alprazolam, a drug sold by Pfizer Inc. as Xanax | Anxiety |
Pilot pharmacokinetic trial demonstrated therapeutic ranges of the drug in the blood (4/27) |
Pozen Inc. |
Trexima (MT400) |
Single-tablet combination of sumatriptan (5-T1B/1D agonist) and naproxen | Migraine |
Second of two pivotal Phase III trials achieved statistical significance for all regulatory endpoints; NDA submission is planned for 3Q:05 (4/21) |
Sepracor |
Lunesta |
Eszopiclone tablets |
Insomnia | Second six-month, Phase IIIb/IV trial in 828 patients showed statistically significant improvements vs. placebo in various efficacy endpoints (4/11) |
Somaxon |
-- |
Low dose of the approved depression drug doxepin | Insomnia |
Phase II trial in 71 elderly patients demonstrated efficacy in primary and all secondary endpoints (4/21) |
Targacept |
Ispronicline (TC-1734) |
Agonist at neuronal nicotinic acetylcholine receptors | Memory impairment |
Began a trial that will include 174 patients between 50 and 80 years of age (4/22) |
XenoPort |
XP13512 |
Transported prodrug of gabapentin (Pfizer Inc.'s Neurontin) | Post-herpetic neuralgia |
Phase IIa trial in 101 patients showed a statistically significant reduction in pain vs. placebo (4/7) |
DIABETES | ||||
ConjuChem |
DAC:GLP-1 |
Insulinotropic hormone GLP-1 created with firm's DAC technology | Type II diabetes |
Additional data from 81 patients in Phase II trial showed reduced blood glucose levels; further trials will be run with a new dilutent (4/18) |
INFECTION | ||||
Acambis plc |
MVA3000 |
Modified vaccinia ankara attenuated smallpox vaccine | Smallpox infection |
Phase I trial in 88 healthy subjects showed no serious adverse events (4/28) |
Corus Pharma |
Cayston (Corus 1020) |
Aztreonam lysinate formulated for inhalation | P. aeruginosa infections in cystic fibrosis | Began AIR-CF2 Phase III trial to test safety and efficacy in cystic fibrosis patients (4/25) |
Genzyme Corp. |
Tolevamer |
Non-antibiotic polymer therapy | C. difficile- associated diarrhea |
Began a Phase III trial that will compare the drug to vancomycin in more than 1,000 patients (4/4) |
GenVec Inc. |
-- |
Adenovector vaccine containing three HIV antigens | HIV |
Phase I trials in 36 healthy volunteers showed the vaccine was well tolerated and immunogenic at each dose level (4/15) |
Gilead Sciences |
Truvada (FDA-approved) | Combination of the approved drugs Emtriva and Viread | HIV |
Study of drug plus Bristol-Myers Squibb Co.'s Sustiva failed to demonstrate bioequivalence; new formulations are being tested (4/26) |
Human Genome |
Albuferon |
Long-acting form of interferon alpha that uses the company's albumin fusion technology | Hepatitis C |
Phase II trial showed the drug was well tolerated, had a prolonged half-life and showed antiviral activity, with durable dose-dependent reductions in viral load (4/14) |
Idenix |
NM283 |
Valopicitabine; oral nucleoside analogue | Hepatitis C |
Phase IIa data from nine patients taking drug and pegylated interferon showed a 99.99% reduction in viral load at 24 weeks (4/14) |
Metabasis |
Pradefovir (formerly remofovir) | Prodrug of the approved HBV drug adefovir (Gilead Sciences Inc.'s Hepsera) | Hepatitis B |
Partner Valeant Pharmaceuticals Inc. presented data on 40 patients showing drug was well tolerated and associated with reductions in serum HBV DNA (4/22) |
MedImmune |
-- |
Intranasal vaccine using an attenuated parainfluenza virus type-3 | Respiratory syncytial virus |
Began Phase I trial to evaluate safety, tolerability and immunogenicity in 120 healthy adults (4/15) |
Osel Inc.* |
Lactin-V | Vaginal capsule containing a natural human bacterial organism vaginosis | Urinary tract infection and bacterial |
Began Phase II trials in the recurrent form of each indication (4/12) |
Theravance |
Telavancin |
Lipoglycopeptide antibiotic believed to have multiple mechanisms of action | Infections |
Presented data from Phase I trials that showed positive pharmacokinetics (4/7) |
Vical Inc. |
-- |
Two formulations of the company's vaccine against cytomegalovirus | Cytomegalovirus infection |
Phase I trials of the bivalent and trivalent formulations demonstrated safety; a Phase II trial of the bivalent formulation is being planned (4/27) |
Vical Inc. |
-- |
Vaccine encoding two surface proteins of the West Nile virus | West Nile virus |
The National Institutes of Health began a trial to evaluate safety and immune responses in 15 healthy volunteers (4/19) |
MISCELLANEOUS | ||||
Ardana plc (UK; |
EP-1572 |
Orally available peptidomimetic; growth hormone secretagogue | Growth hormone and other disorders |
Phase I trial in 36 male volunteers showed the drug induced a significant rise in growth hormone levels (4/19) |
BioMarin |
Phenoptin |
Sapropterin hydrochloride; form of the enzyme co-factor 6R-BH4 | Phenylketonuria |
Began a Phase III trial to assess safety and reductions in blood Phe levels in 100 patients (4/7) |
CollaGenex |
COL-3 |
Second-generation agent from the company's inhibitors of multiple proteases and cytokines program | Rosacea |
Phase II trial in 13 patients showed those treated with drug had significantly fewer inflammatory lesions than those on placebo (4/15) |
Discovery |
Surfaxin |
Engineered version of natural human lung surfactant | Respiratory distress syndrome in premature babies | Published data from Phase III SELECT and STAR trials showed drug provides potential advantages to existing surfactant therapy (4/4) |
DOR BioPharma |
orBec |
Oral formulation of beclomethasone dipropionate; a corticosteroid | Graft-vs.-host disease |
Said it intends to file an NDA; Phase III data released in December showed a missed primary endpoint but efficacy on secondary endpoints (4/20) |
Evolutec |
rEV131 |
Histamine-binding protein | Allergic rhinitis |
Is starting a Phase II trial in 80 patients to assess improvement in nasal symptoms vs. placebo (4/18) |
Genzyme |
Myozyme |
Recombinant human acid alpha-lucosidase enzyme | Pompe disease |
Interim analysis in pivotal trial in 18 patients showed likelihood of meeting primary endpoint; a BLA filing is planned for mid-2005 (4/25) |
Hemispherx |
Ampligen |
RNA drug with potential action as an immuno-modulator and antiviral | Chronic fatigue syndrome |
Presented data from trials showing drug improved exercise duration vs. both approved drugs and placebo (4/11) |
Insmed Inc. |
SomatoKine |
Composition of insulin-like growth factor-1 and its primary binding protein, BP3 | HIV-associated lipodystrophy |
Began a Phase II trial to evaluate safety and efficacy for 12 weeks in 12 patients (4/20) |
Inspire |
INS37217 Ophthalmic |
Denufosol tetrasodium; P2Y2 receptor agonist | Macular edema and retinal detachment |
Phase II trial in retinal detachment is being stopped due to slow enrollment; pilot Phase II trials in macular edema are being planned (4/27) |
Inspire |
Diquafosol tetrasodium | Ophthalmic solution; P2Y2 receptor agonist | Corneal wound healing |
Began pilot trial to test drug vs. placebo in 30 patients following photorefractive keratectomy (4/27) |
Karo Bio |
-- |
Estrogen receptor compound | Various conditions |
Partner Merck & Co. Inc. stopped a Phase I trial of the lead drug from their collaboration after adverse findings in ongoing animal studies (4/11) |
Neurochem |
Fibrillex |
Glycosaminoglycan mimetic with anti-amyloid properties | Amyloid A amyloidosis |
Phase II/III trial in 183 patients showed improved kidney function measurements and death vs. placebo, but failed to reach statistical significance (4/18) |
NPS |
Preos |
Recombinant human parathyroid hormone | Osteoporosis |
Two analyses of Phase III TOP trial data corroborate earlier data showing improved bone microarchitecture and reduced vertebral fractures in high-risk postmenopausal osteoporotic women (4/7) |
Omeros Corp.* |
OMS103HP | Targeted therapeutic agent delivered directly to a surgical site | Improvement in knee function |
Began Phase III trial to test drug in 900 patients undergoing arthroroscopic anterior cruciate ligament reconstruction (4/12) |
Osiris |
Chondrogene |
Formulation of adult mesenchymal stem cells | Regeneration of meniscus tissue |
Began Phase I/II trial to evaluate safety and efficacy in 48 knee surgery patients (4/1) |
Palatin Technologies |
PT-141 |
Intranasally delivered melanocortin agonist | Erectile dysfunction |
Trial with Viagra in 19 patients showed enhanced duration and quality of erectile activity vs. Viagra monotherapy (4/18) |
PTC |
PTC124 |
Oral agent that targets nonsense mutations | Various disorders |
Phase I trial showed target plasma concentrations were achieved and no drug-related adverse events were seen (4/11) |
Rigel |
R112 |
Intranasal agent designed to interrupt the signal from the IgE receptor | Allergic rhinitis |
Phase II trial showed patients in a park-like setting had significant improvements in symptoms, and confirmed tolerability and safety (4/6) |
Vivus Inc. |
Avanafil (TA-1790) |
Oral phosphodiesterase type-5 inhibitor | Erectile dysfunction |
Trial to test hemodynamic responses to glyceryl trinitrate showed drug compared favorably to Viagra (4/25) |
Notes: | ||||
* Privately held. | ||||
BLA = Biologics license application; EMEA = European Medicines Agency; FDA = Food and Drug Administration; IND = Investigational new drug application; MAA = Marketing authorization application; NDA = New drug application; SPA = Special protocol assessment. | ||||
Unless otherwise noted, the stock symbols listed for public companies are on the Nasdaq market. | ||||
AIM = Alternative Investment Market; AMEX = American Stock Exchange; ASX = Australian Stock Exchange; CSE = Copenhagen Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SSE = Stockholm Stock Exchange; TSE = Toronto Stock Exchange. | ||||
